UPDATE: Goldman Downgrades Puma Biotechnology To Sell, Lowers Target To $8 As Firm Notes 'we think the headline risk from upcoming competitive data at YE2019 from SGEN's tucatinib (link) is underappreciated and creates a challenging set up'